Oramed receives $18M payment from Scilex, approves $0.25/share dividend

ORAMED PHARMACEUTICALS INC.

$18M payment from Scilex closes Option Agreement; current returns total $118M on $99.5M investment.
Retains $27M note, $12M convertible note ($36/share option), warrants, and nine-year royalty interest.
Board approves $0.25/share cash dividend; payable Jan 26, 2026 to holders of record Jan 16, 2026.
Aggregate dividend ~$10.5M, funded from surplus capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.